CA
SLS icon

Cliff Asness’s SELLAS Life Sciences SLS Stock Holding History

Cliff Asness’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$858K Buy
58,120
+4,130
+8% +$28.5K ﹤0.01% 3088
2026
Q1 		$228K Buy
+53,990
New +$242K ﹤0.01% 3543

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.31% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Cliff Asness's SLS Position: Q2 2026 in Review

Cliff Asness increased its SELLAS Life Sciences (SLS) stake by 7.6% in Q2 2026, buying an estimated $28.5K and bringing the position to 58,120 shares worth $858K. The position accounts for ﹤0.01% of the portfolio, ranked #3088.

Cliff Asness first reported a position in SLS in Q1 2026 and has held it in 2 quarters since. 190 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Cliff Asness held 58,120 shares of SELLAS Life Sciences worth $858K as of Q2 2026.
  • Cliff Asness bought 4,130 SELLAS Life Sciences shares in Q2 2026, an estimated $28.5K.
  • SELLAS Life Sciences made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3088 holding.
  • Cliff Asness first reported a position in SELLAS Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 190 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.